PharVision Advisers LLC acquired a new stake in InMode Ltd. (NASDAQ:INMD - Free Report) during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor acquired 32,019 shares of the healthcare company's stock, valued at approximately $535,000.
Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Strategic Global Advisors LLC grew its stake in shares of InMode by 3.0% in the 4th quarter. Strategic Global Advisors LLC now owns 20,744 shares of the healthcare company's stock valued at $346,000 after buying an additional 604 shares in the last quarter. Harvey Capital Management Inc. lifted its stake in InMode by 1.4% in the fourth quarter. Harvey Capital Management Inc. now owns 51,490 shares of the healthcare company's stock valued at $860,000 after acquiring an additional 700 shares during the last quarter. Thrivent Financial for Lutherans grew its position in InMode by 6.1% in the fourth quarter. Thrivent Financial for Lutherans now owns 12,586 shares of the healthcare company's stock worth $210,000 after acquiring an additional 721 shares in the last quarter. Covestor Ltd grew its position in InMode by 13.9% in the fourth quarter. Covestor Ltd now owns 5,936 shares of the healthcare company's stock worth $99,000 after acquiring an additional 723 shares in the last quarter. Finally, Farther Finance Advisors LLC increased its stake in shares of InMode by 26.2% during the 4th quarter. Farther Finance Advisors LLC now owns 5,555 shares of the healthcare company's stock worth $93,000 after purchasing an additional 1,154 shares during the last quarter. Hedge funds and other institutional investors own 68.04% of the company's stock.
InMode Stock Performance
Shares of InMode stock traded down $0.10 during trading on Monday, reaching $14.23. The company's stock had a trading volume of 774,297 shares, compared to its average volume of 1,188,157. InMode Ltd. has a one year low of $13.68 and a one year high of $19.85. The firm has a market cap of $899.46 million, a price-to-earnings ratio of 6.06 and a beta of 2.02. The business's fifty day moving average price is $15.61 and its 200-day moving average price is $17.20.
InMode (NASDAQ:INMD - Get Free Report) last released its earnings results on Monday, April 28th. The healthcare company reported $0.31 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.45 by ($0.14). InMode had a net margin of 45.91% and a return on equity of 18.25%. The business had revenue of $77.87 million during the quarter, compared to analyst estimates of $82.21 million. During the same period last year, the business earned $0.32 EPS. The business's quarterly revenue was down 3.0% compared to the same quarter last year. Sell-side analysts anticipate that InMode Ltd. will post 1.75 EPS for the current year.
Wall Street Analyst Weigh In
INMD has been the subject of several analyst reports. BTIG Research cut shares of InMode from a "buy" rating to a "neutral" rating in a report on Tuesday, April 29th. Needham & Company LLC reaffirmed a "hold" rating on shares of InMode in a research report on Monday, April 28th. UBS Group lowered their price objective on InMode from $19.00 to $16.25 and set a "neutral" rating on the stock in a report on Tuesday, April 29th. Robert W. Baird downgraded InMode from an "outperform" rating to a "neutral" rating and cut their price objective for the company from $22.00 to $16.00 in a research note on Monday, April 28th. Finally, Barclays decreased their target price on InMode from $29.00 to $24.00 and set an "overweight" rating for the company in a research report on Wednesday, April 30th. Seven analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus price target of $18.54.
Check Out Our Latest Stock Report on INMD
InMode Company Profile
(
Free Report)
InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.
Featured Articles

Before you consider InMode, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and InMode wasn't on the list.
While InMode currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.